March 20, 2019 / 2:48 PM / a month ago

Novo Nordisk submits diabetes pill for U.S. approval

COPENHAGEN, March 20 (Reuters) - Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for U.S. approval.

The Danish drugmaker said on Wednesday it had used a so-called priority review voucher to speed up the anticipated review time of the drug to six months.

The once-daily pill, a key growth hope for the company, belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production.

So far, all have been injections and a pill would offer a step-change to overcome the aversion many diabetics have to injections.

Novo Nordisk hopes to launch the pill in 2020. (Reporting by Stine Jacobsen; Editing by Kirsten Donovan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below